Veracyte's (VCYT) progress with the three long-term growth drivers exhibits robust growth potential for the upcoming quarters. The record volume growth of the Decipher Prostrate test instills optimism, supported by the distinct recognition from the NCCN (National Comprehensive Cancer Network). The Afirma GRID offering can help the company extend its reach into the endocrinology market. Meanwhile, declining biopharma revenues and macroeconomic issues are worries for Veracyte. In the past year, this Zacks Ran ...

A month has gone by since the last earnings report for Veracyte (VCYT) . Shares have added about 9.2% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Veracyte due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Veracyte's Q2 Earnings Top Estimates,'24 Sales View Up Ver ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? Developed alo ...

After reaching an important support level, Veracyte, Inc. (VCYT) could be a good stock pick from a technical perspective. VCYT recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average. There's a reason traders love a golden cross -- it's a technical chart pattern that can indicate a bullish breakout is on the horizon. This kind of crossover is formed when a stock's short-term moving average breaks above a longer-term moving ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style ...

Have you been paying attention to shares of Veracyte (VCYT) ? Shares have been on the move with the stock up 27.4% over the past month. The stock hit a new 52-week high of $32.86 in the previous session. Veracyte has gained 18.3% since the start of the year compared to the 8.2% move for the Zacks Medical sector and the 6.2% return for the Zacks Medical - Instruments industry. What's Driving the Outperformance? The stock has an impressive record of positive earnings surprises, as it hasn't missed our earning ...

Veracyte (VCYT) delivered second-quarter 2024 adjusted diluted earnings of 30 cents per share, up a stupendous 150% from the year-ago period's level. The reported figure beat the Zacks Consensus Estimate of a loss of 3 cents per share. Revenues Revenues increased 26.7% year over year to $114.4 million, which outpaced the Zacks Consensus Estimate by 14%. Segmental Details Testing revenues totaled $107 million in the reported quarter, up 31% year over year. This rise was mainly due to increased Decipher and A ...

On Tuesday, Veracyte, Inc VCYT reported second-quarter sales of $114.43 million, up 27% year over year, beating the consensus of $100.3 million. Testing revenue was $107.0 million, an increase of 31%, driven by the strong performance of our Decipher Prostate and Afirma tests. Total test volume grew to 39,023, an increase of 23% compared to the second quarter of 2023. During the quarter, the company achieved a record Decipher Prostate test volume of close to 19,900 tests, driven by recently updated NCCN pros ...

分组1 - Veracyte reported quarterly earnings of $0.30 per share, exceeding the Zacks Consensus Estimate of a loss of $0.03 per share, and compared to a loss of $0.12 per share a year ago, representing an earnings surprise of 1,100% [1] - The company achieved revenues of $114.43 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 14.04%, and up from $90.32 million year-over-year [2] - Veracyte has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance [2] 分组2 - The stock has underperformed the market, losing about 23.7% since the beginning of the year, while the S&P 500 gained 8.7% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.05 on revenues of $101.22 million, and for the current fiscal year, it is -$0.05 on revenues of $406.07 million [7] - The Medical - Instruments industry, to which Veracyte belongs, is currently in the top 40% of Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8]

This molecular diagnostic company is expected to post quarterly loss of $0.03 per share in its upcoming report, which represents a year-over-year change of +75%. Revenues are expected to be $100.34 million, up 11.1% from the year-ago quarter. For Veracyte, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on VCYT going forward ...